Gastrointestinal Cancers (BG Czito, Section Editor)

Current Oncology Reports

, Volume 15, Issue 2, pp 182-189

First online:

The Role of the FOLFIRINOX Regimen for Advanced Pancreatic Cancer

  • Thierry ConroyAffiliated withEA 4360 and Department of Medical Oncology, Centre Alexis Vautrin, Université de LorraineDepartment of Medical Oncology, Centre Alexis Vautrin Email author 
  • , Céline GavoilleAffiliated withDepartment of Medical Oncology, Centre Alexis Vautrin
  • , Emmanuelle SamalinAffiliated withDepartment of Medical Oncology, Centre Val d’Aurelle
  • , Marc YchouAffiliated withDepartment of Medical Oncology, Centre Val d’Aurelle
  • , Michel DucreuxAffiliated withDepartment of Medicine, Institut Gustave Roussy

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access


In 2010, the FOLFIRINOX regimen (bolus and infusional 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin) emerged as a new option in patients with metastatic pancreatic cancer and a good performance status. However, at that time, some doubts were raised regarding safety issues. Similarly, no data on FOLFIRINOX were published in patients with unresectable/locally advanced or borderline resectable pancreatic cancer. This article presents the available experience with FOLFIRINOX outside clinical trials in metastatic and locally advanced pancreatic cancer patients. The safety of the regimen in patients with biliary stents and in previously treated patients is also described. FOLFIRINOX usage in clinical practice, including modification of the regimen (omission of bolus 5-fluorouracil; FOLFOXIRI regimen), is also presented. These data suggest that a phase III randomized study is warranted to further explore the role of FOLFIRINOX in locally advanced pancreatic cancer.


Pancreatic cancer Chemotherapy Oxaliplatin Irinotecan